Trial · NCT07886359
Effects of Supervised Aerobic Exercise on Biomarkers in Patients With nSCLC Receiving Immunotherapy
NCT07886359, Not applicable, Not yet recruiting, Izmir Bakircay University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Supervised Aerobic Exercise on Biomarkers in Patients With nSCLC Receiving Immunotherapy. Trials, record NCT07886359. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886359
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Supervised Aerobic Exercise on Biomarkers in Patients With nSCLC Receiving Immunotherapy
- NCT number
- NCT07886359
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 78 participants, estimated
- Lead sponsor
- Izmir Bakircay University
- Conditions
- Non-Small Cell Lung Cancer, Aerobic Exercise, Immunotherapy, Biomarker, Tumor Microenvironment, Handgrip Strength, Quality of Life
- Interventions
- Exercise
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Analysis of Serum Biomarkers (Serum CXCL9,CXCL11,CCL2,CCL5,IFN-γ,IL-10 concentration) | Before immunotherapy, week 12 and week 24 | Serum CXCL9,CXCL11,CCL2,CCL5,IFN-γ,IL-10 concentrations will be measured using ELISA. Results will be expressed in pg/mL. |
| Primary | Assesment of Absolute CD3+ , CD4+ , CD8+ , CD19+ T-lymphocyte counts, CD16/56+ Natural Killer cells | Before immunotherapy, week 12 and week 24 | Absolute CD3+ , CD4+ , CD8+ , CD19+ T-lymphocyte counts, CD16/56+ Natural Killer cells will be assessed by flow cytometry using the BD Multitest™ 6-Color TBNK reagent and BD FACSLyric™ flow cytometer. Absolute counts will be calculated using a dual-platform approach incorporating routine complete blood count data. Results will be expressed in cells/µL. |
| Primary | Analysis of Handgrip Strength | Before immunotherapy, week 12 and week 24 | Handgrip strength will be evaluated via hand dynamometer while one is upright seated in an armless chair, elbow flexed 90 degree and forearm positioned at midprone. Three repetitions will be collected, the mean of them will be recorded. Handgrip strength will be recorded as kilogram (kg). |
| Primary | Peripheral muscle strength | Before immunotherapy, week 12 and week 24 | Participants' peripheral muscle strength will be assessed using a digital hand dynamometer (LaFayette Manual Muscle Tester) to measure knee extension of the quadriceps femoris muscle, with three repetitions on each side; measurements will be recorded in Newtons. Peripheral muscle strength will be recorded as Newton (N). |
| Primary | Cardiorespiratory endurance assessment | Before immunotherapy, week 12 and week 24 | Cardiorespiratory endurance will be evaluated via the six minute walk test and total walking distance will be recorded in meters (m). |
| Secondary | Assessment of Quality of Life | Before immunotherapy, week 12 and week 24 | Participants' quality of life will be assessed using the European Organization for Research and Treatment of Cancer to assess health-related quality of life in patients with lung cancer questionnaire (EORTC-QLQ-LC29), which was developed specifically for lung cancer patients by the European Organization for Research, Treatment and Cancer and has been proven to be valid and reliable. Higher scores indicate worse quality of life. The minimum and maximum values are ranged between 0 and 100. |
| Secondary | Fatigue Assessment | Before immunotherapy, week 12 and week 24 | Fatigue will be assessed using the European Organization for Research and Treatment of Cancer to assess fatigue in patients with cancer (EORTC-QLQ-FA12).Higher scores indicate higher perceived fatigue. The minimum and maximum values are ranged between 0 and 100. |
| Secondary | Body fat percentage | Before immunotherapy, week 12 and week 24 | Body fat percentage will be evaluated via Tanita-BC-420 MA. It will be recorded as %(percentage). |
| Secondary | Skeletal Muscle Mass | Before immunotherapy, week 12 and week 24 | Skeletal Muscle Mass will be evaluated via Tanita-BC-420 MA. It will be recorded as kilogram (kg). |
| Secondary | Fat free mass | Before immunotherapy, week 12 and week 24 | Fat free mass will be evaluated via Tanita-BC-420 MA. It will be recorded as kilogram (kg). |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886359
GET https://conductscience.org/api/trials/v1/NCT07886359/registered